Publicaciones en las que colabora con JA Pérez-Simón (19)

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

  2. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2022

  1. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2012

  1. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation

    Haematologica, Vol. 97, Núm. 9, pp. 1329-1337

2011

  1. Reply to A. Gratwohl

    Journal of Clinical Oncology

2010

  1. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting

    Blood, Vol. 115, Núm. 1, pp. 107-121

  2. International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

    Journal of Clinical Oncology, Vol. 28, Núm. 29, pp. 4521-4530

2008

  1. Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 6, pp. 664-671

2007

  1. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation

    Haematologica, Vol. 92, Núm. 9, pp. 1295-1296

2006

  1. Bone marrow mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation

    Experimental Hematology

  2. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

    Bone Marrow Transplantation, Vol. 37, Núm. 12, pp. 1135-1141

  3. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma [8]

    Blood

  4. Trasplante de progenitores hematopoyéticos

    Trasplante de órganos y células : dimensiones éticas regulatorias (Fundación BBVA), pp. 253-274

2004

  1. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

    Bone Marrow Transplantation, Vol. 33, Núm. 2, pp. 183-187

  2. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

    Blood, Vol. 103, Núm. 11, pp. 4056-4061

  3. Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation

    Leukemia and Lymphoma, Vol. 45, Núm. 9, pp. 1725-1729

  4. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

    Biology of Blood and Marrow Transplantation, Vol. 10, Núm. 10, pp. 698-708

2003

  1. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

    British Journal of Haematology, Vol. 121, Núm. 1, pp. 104-108